Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Athira Pharma (ATHA) to $4 from $5 and keeps a Neutral rating on the shares following the 10-for-1 reverse stock split. The split has no impact on the company’s underlying fundamentals, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHA:
- Athira Pharma trading halted, news pending
- Upcoming Stock Splits This Week (September 15 to September 19) – Stay Invested
- Athira Pharma Announces 10-for-1 Reverse Stock Split
- Athira Pharma announces a 10-for-1 reverse stock split
- Athira Pharma presents results from Phase 1 trial of ATH-1105 at ALS Nexus